Atlas Trials

Grit Biotechnology

30 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Grit Biotechnology

RecordFirmDate
A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT07676006)Grit Biotechnology2026-07-01
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases (NCT07389499)Grit Biotechnology2026-05-30
A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors (NCT07534813)Grit Biotechnology2026-04-30
A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD) (NCT07253259)Grit Biotechnology2025-12-18
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases (NCT07333118)Grit Biotechnology2025-11-07
GT719 Injection for Moderate to Severe Refractory Autoimmune Disease (NCT07132112)Grit Biotechnology2025-10-28
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia (NCT07205315)Grit Biotechnology2025-09-26
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases (NCT07122076)Grit Biotechnology2025-08-22
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies (NCT06948981)Grit Biotechnology2025-04-18
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors (NCT07131254)Grit Biotechnology2025-03-10
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases (NCT07021209)Grit Biotechnology2025-01-14
Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer (NCT06519669)Grit Biotechnology2024-07-18
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours (NCT06453057)Grit Biotechnology2024-07-04
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer (NCT06819280)Grit Biotechnology2024-06-28
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors (NCT06190275)Grit Biotechnology2024-05-12
Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours (NCT06397963)Grit Biotechnology2024-04-18
GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer (NCT06235242)Grit Biotechnology2024-02-02
GT201 Injection For The Treatment Of Advanced Solid Tumors (NCT06144671)Grit Biotechnology2023-09-13
Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer) (NCT06191900)Grit Biotechnology2023-06-05
Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors) (NCT06145802)Grit Biotechnology2023-03-09
Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors (NCT06094426)Grit Biotechnology2023-02-26
Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (NCT06834542)Grit Biotechnology2022-11-01
Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors (NCT05729399)Grit Biotechnology2022-09-14
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors (NCT05430373)Grit Biotechnology2022-05-23
Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors (NCT05430360)Grit Biotechnology2022-01-04
GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors (NCT06077903)Grit Biotechnology2021-07-05

Track Grit Biotechnology automatically

Every clearance here is in the API, with alerts when new ones post.